Logo image of ECX.DE

EPIGENOMICS AG (ECX.DE) Stock Price, Quote, News and Overview

FRA:ECX - Deutsche Boerse Ag - DE000A37FT41 - Common Stock - Currency: EUR

0.7  -0.09 (-11.17%)

ECX.DE Quote, Performance and Key Statistics

EPIGENOMICS AG

FRA:ECX (6/27/2024, 7:00:00 PM)

0.7

-0.09 (-11.17%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.4
52 Week Low0.3
Market Cap23.90K
Shares34.14K
Float29.02K
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)09-30 2024-09-30
IPO07-19 2004-07-19


ECX.DE short term performance overview.The bars show the price performance of ECX.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ECX.DE long term performance overview.The bars show the price performance of ECX.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40

The current stock price of ECX.DE is 0.7 EUR. In the past month the price decreased by -57.32%. In the past year, price increased by 52.84%.

EPIGENOMICS AG / ECX Daily stock chart

ECX.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 16.41 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 248.77 33.10B
22UA.DE BIONTECH SE-ADR N/A 23.75B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.76 19.21B
0QF.DE MODERNA INC N/A 12.84B

About ECX.DE

Company Profile

ECX logo image Epigenomics AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Berlin, Berlin and currently employs 18 full-time employees. The company went IPO on 2004-07-19. Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.

Company Info

EPIGENOMICS AG

Geneststrasse 5

Berlin BERLIN DE

Employees: 18

Company Website: https://www.epigenomics.com/

Phone: 4930243450

EPIGENOMICS AG / ECX.DE FAQ

What is the stock price of EPIGENOMICS AG today?

The current stock price of ECX.DE is 0.7 EUR. The price decreased by -11.17% in the last trading session.


What is the ticker symbol for EPIGENOMICS AG stock?

The exchange symbol of EPIGENOMICS AG is ECX and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is ECX.DE stock listed?

ECX.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for EPIGENOMICS AG stock?

6 analysts have analysed ECX.DE and the average price target is 16.32 EUR. This implies a price increase of 2231.43% is expected in the next year compared to the current price of 0.7. Check the EPIGENOMICS AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EPIGENOMICS AG worth?

EPIGENOMICS AG (ECX.DE) has a market capitalization of 23.90K EUR. This makes ECX.DE a Nano Cap stock.


How many employees does EPIGENOMICS AG have?

EPIGENOMICS AG (ECX.DE) currently has 18 employees.


What are the support and resistance levels for EPIGENOMICS AG (ECX.DE) stock?

EPIGENOMICS AG (ECX.DE) has a resistance level at 1.72. Check the full technical report for a detailed analysis of ECX.DE support and resistance levels.


Is EPIGENOMICS AG (ECX.DE) expected to grow?

The Revenue of EPIGENOMICS AG (ECX.DE) is expected to grow by 2136.83% in the next year. Check the estimates tab for more information on the ECX.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EPIGENOMICS AG (ECX.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EPIGENOMICS AG (ECX.DE) stock pay dividends?

ECX.DE does not pay a dividend.


When does EPIGENOMICS AG (ECX.DE) report earnings?

EPIGENOMICS AG (ECX.DE) will report earnings on 2024-09-30.


What is the Price/Earnings (PE) ratio of EPIGENOMICS AG (ECX.DE)?

EPIGENOMICS AG (ECX.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.68).


ECX.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ECX.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ECX.DE. ECX.DE has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ECX.DE Financial Highlights

Over the last trailing twelve months ECX.DE reported a non-GAAP Earnings per Share(EPS) of -17.68. The EPS decreased by -7359.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -386.29%
ROE -853.33%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%-3779.63%
Sales Q2Q%-44.44%
EPS 1Y (TTM)-7359.64%
Revenue 1Y (TTM)-92.8%

ECX.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to ECX.DE. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 47.75% and a revenue growth 2136.83% for ECX.DE


Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price Target16.32 (2231.43%)
EPS Next Y47.75%
Revenue Next Year2136.83%